Aperiam Bio, a NYC-based protein engineering company, raised $9M in Seed funding.
The round was led by OMX Ventures, with participation from Axial VC, KDT Ventures and Civilization Ventures.
The company intends to use the funds to expand R&D for its wholly owned products and advance its work to-date building partnerships with companies that are tackling the wide array of problems where pulmonary products are the solution.
Led by Founder and CEO Austin Cole, Aperiam Bio is a protein and pulmonary product company. It applies a patented, 3D computer vision algorithm – akin to ‘facial recognition for proteins’ – to identify succinct, targeted improvements to proteins that make them more effective and durable than they are in nature.
Aperiam Bio has demonstrated its algorithms create product-enabling increases to proteins’ chemical, thermal, and mechanical stress tolerance by:
- Increasing the luminance of the blue fluorescent protein (BFP) by 10x and strengthening the protein’s chemical and thermal stress tolerance.
- More than doubling a wholly-owned protein’s tolerance to nebulization, thereby unlocking therapeutic protein delivery to the lung.
- Showing intended efficacy of this improved protein in an animal model, thereby unlocking a whole class of pulmonary biologic products.
Headquartered in Brooklyn, New York, the company was founded on technology built at the University of Texas.
FinSMEs
29/11/2023